Semax Protocol
Dosing & Research
Last Updated: April 22, 2026
Attention and executive-function research, Neuroprotection, BDNF/NGF signaling, Stroke recovery models
Evidence Level
Human Clinical Data Available
Species Studied
Human • Rat • Mouse
Half-Life
Short; often cited in minutes with longer pharmacodynamic effects
Administration
• Intranasal
• Subcutaneous
Frequency
Daily or 3-5x weekly; avoid evening to prevent sleep disruption
How It Works
- Attention and executive-function research
- Neuroprotection
- BDNF/NGF signaling
- Stroke recovery models
Dosing Structure
Dose
0.5–1 mg
Frequency
Daily or 3-5x weekly; avoid evening to prevent sleep disruption
Notes
Daily SubQ: 100-300mcg. 3x-5x per week SubQ: 200-500mcg (some protocols call for a max of 1mg per day). Intranasal: 750mcg-1mg. Should avoid taking Semax at night to prevent sleep disruptions. Cycle Durations: Daily: 1 month on, 1 month off. 3-5x per week: 2 months on, 2 months off. Break: 1-2 weeks between cycles to maintain effectiveness.
Example Protocols
Dose: 0.5–1 mg
Frequency: Daily or 3-5x weekly; avoid evening to prevent sleep disruption
Duration: 8 Weeks
Off Period: Not listed
Protocol Notes
•
Daily SubQ: 100-300mcg.
•
3x-5x per week SubQ: 200-500mcg (some protocols call for a max of 1mg per day).
•
Intranasal: 750mcg-1mg.
•
Should avoid taking Semax at night to prevent sleep disruptions.
•
Cycle Durations: Daily: 1 month on, 1 month off.
•
3-5x per week: 2 months on, 2 months off.
•
Break: 1-2 weeks between cycles to maintain effectiveness.
Research & Studies
Loading citations…
- Curated References
- CuratedPubMedPMID 17217149Semax affects the expression of genes related to the immune and vascular systems in rats↗Bull Exp Biol Med · 2003 · Grigoriev VV, Dranyi OA, Bachurin SO.humanstrokedosingclinical
- CuratedPubMedPMID 20559768Intranasal Semax administration increases BDNF, NGF, and GDNF in the rat brain↗J Neurochem · 2006 · Dolotov OV, Karpenko EA, Inozemtseva LS, et al.mechanismBDNFNGFanimal
- CuratedPubMedPMID 22289155The neuroprotective and neurorestorative properties of Semax↗J Mol Neurosci · 2012 · Arkhipova NA, Kozlovskaya MM.neuroprotectionmechanismclinical
Research Feedback
0 approved
For research discussion only. Community feedback is moderated and shown here as aggregated insights after approval.
Be the first to submit research feedback for this peptide.
Approved submissions will appear here as aggregated insights.